Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANDALL T HULING

Allopathic & Osteopathic Physicians Family Medicine

NPI
1316936917
CMS profile
105086
Location
OLIVE BRANCH, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$13,903.27

66 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $12,926.95 34
Food and Beverage $976.32 32

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANDALL T HULING

NPI 1316936917 · CMS profile ID 105086

Allopathic & Osteopathic Physicians / Family Medicine

OLIVE BRANCH, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316936917?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANDALL T HULING, NPI 1316936917, CMS profile ID 105086. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316936917?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RANDALL T HULING, NPI 1316936917, CMS profile ID 105086. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316936917?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RANDALL T HULING, NPI 1316936917, CMS profile ID 105086, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1316936917?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

66 matching records · $13,903.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 66 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–66 of 66.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $1,123.5003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078721 CMS
Eli Lilly and Company $914.8503/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078725 CMS
Eli Lilly and Company $199.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078729 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078733 CMS
Eli Lilly and Company $34.9803/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078735 CMS
Eli Lilly and Company $1,364.2503/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078739 CMS
Eli Lilly and Company $13.9303/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078743 CMS
Eli Lilly and Company $199.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078747 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078751 CMS
Eli Lilly and Company $24.9903/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078755 CMS
Eli Lilly and Company $199.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032101877 CMS
Eli Lilly and Company $450.4303/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032101881 CMS
Eli Lilly and Company $24.9903/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032101885 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032125345 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032125349 CMS
Eli Lilly and Company $199.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032125353 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,784.58 60
PY2020 $5,637.66 34
PY2021 $655.21 43
PY2022 $416.63 27
PY2023 $13,903.27 66
PY2024 $348.30 16
PY2025 $228.62 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,283,339.91 174
PY2024 Recipient $17,894.47 4
PY2024 Principal investigator $964,308.98 57
PY2023 Recipient $150.00 1
PY2023 Principal investigator $253,730.06 13
PY2022 Recipient $684.00 2
PY2022 Principal investigator $173,811.70 18
PY2021 Principal investigator $999,356.23 35
PY2020 Recipient $3,097.60 3
PY2020 Principal investigator $516,756.40 68
PY2019 Recipient $31,324.01 9
PY2019 Principal investigator $363,273.68 75

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

174 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $5,571.00 12/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634603
Principal investigator 1 Genentech, Inc. $3,432.00 12/19/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.10 12/19/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 12/19/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $747.00 12/19/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,963.95 12/19/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,210.09 12/11/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274759
Principal investigator 1 Genentech, Inc. $5,434.00 12/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $914.94 12/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,420.18 11/25/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264333
Principal investigator 1 Genentech, Inc. $1,716.00 11/20/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,004.63 11/20/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,332.65 11/20/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,921.40 11/20/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $244.98 11/20/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $781.25 11/20/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,210.09 11/20/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 11/19/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center - Clinedge - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508326
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,000.00 11/19/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center - Clinedge - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508330
Principal investigator 1 Janssen Research & Development, LLC $2,367.00 11/19/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237587
Principal investigator 1 Janssen Research & Development, LLC $1,470.00 11/17/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237610
Principal investigator 1 Genentech, Inc. $1,716.00 11/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,630.27 11/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260955
Principal investigator 1 Janssen Research & Development, LLC $5,410.00 11/07/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,551.19 11/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257853
Principal investigator 1 Genentech, Inc. $4,771.00 11/06/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634591
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 11/03/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192109571
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/03/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192109575
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 11/03/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192109596
Principal investigator 1 Janssen Research & Development, LLC $3,299.00 11/03/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237661
Principal investigator 1 Genentech, Inc. $1,482.00 10/29/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,445.27 10/29/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253760
Principal investigator 1 Genentech, Inc. $1,716.00 10/24/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,431.79 10/23/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252782
Principal investigator 1 Genentech, Inc. $4,550.00 10/16/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37,960.30 10/16/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250831
Principal investigator 1 Genentech, Inc. $3,133.00 10/09/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,247.50 10/09/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,843.99 10/03/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244809
Principal investigator 1 Genentech, Inc. $3,055.00 10/01/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634578
Principal investigator 1 Genentech, Inc. $2,704.00 09/24/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634515
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,100.00 09/24/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067705
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,442.00 09/24/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067707
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,044.10 09/24/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,396.93 09/23/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241754
Principal investigator 1 Janssen Research & Development, LLC $5,685.00 09/19/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,158.00 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.91 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,773.56 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $730.35 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $913.00 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,821.85 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,498.64 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $164.96 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,261.02 09/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240692
Principal investigator 1 Genentech, Inc. $2,145.00 09/11/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157,190.16 09/10/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235883
Principal investigator 1 Genentech, Inc. $858.00 09/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,981.08 09/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235295
Principal investigator 1 Genentech, Inc. $490.00 08/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634510
Principal investigator 1 Genentech, Inc. $5,759.00 08/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634528
Principal investigator 1 Genentech, Inc. $497.00 08/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634533
Principal investigator 1 Genentech, Inc. $65.00 08/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634541
Principal investigator 1 Genentech, Inc. $1,080.00 08/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634552
Principal investigator 1 Genentech, Inc. $78.00 08/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634555
Principal investigator 1 Genentech, Inc. $65.00 08/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,734.71 08/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,874.70 08/21/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229799
Principal investigator 1 GlaxoSmithKline, LLC. $3,864.22 08/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192109587
Principal investigator 1 Genentech, Inc. $1,716.00 08/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,942.19 08/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,623.95 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $892.40 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $903.29 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,968.25 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,467.20 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,923.75 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,174.85 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $283.78 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,787.76 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,874.70 08/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,173.15 07/31/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,848.00 07/31/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $623.20 07/31/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,889.65 07/31/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $403.58 07/31/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,816.89 07/31/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222970
Principal investigator 1 Genentech, Inc. $2,373.00 07/23/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634524
Principal investigator 1 Genentech, Inc. $33,143.00 07/23/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,191.05 07/22/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,737.64 07/22/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,009.68 07/22/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.84 07/17/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217240
Principal investigator 1 Genentech, Inc. $2,574.00 07/10/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,140.18 07/10/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214514
Principal investigator 1 Janssen Research & Development, LLC $16,289.00 07/07/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,621.25 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.04 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30,963.60 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,502.75 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,804.50 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $410.02 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,521.00 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,222.34 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38,102.40 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,057.28 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,417.20 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,296.80 07/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212997
Principal investigator 1 F. Hoffmann-La Roche AG $78.00 06/25/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634481
Principal investigator 1 F. Hoffmann-La Roche AG $5,980.00 06/25/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634489
Principal investigator 1 F. Hoffmann-La Roche AG $1,445.00 06/25/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,514.52 06/24/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210730
Principal investigator 1 F. Hoffmann-La Roche AG $2,301.00 06/19/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78,685.84 06/12/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206197
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,750.00 06/06/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center
LX9211 No dispute reported 06/30/2026 1248066701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $359.88 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,579.65 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,212.40 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,056.88 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,139.65 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,506.06 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,651.10 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $996.00 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $132.59 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,193.50 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,281.15 06/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204343
Principal investigator 1 F. Hoffmann-La Roche AG $8,827.00 05/26/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634475
Principal investigator 1 Janssen Research & Development, LLC $223.00 05/14/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237652
Principal investigator 1 F. Hoffmann-La Roche AG $475.00 05/12/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634499
Principal investigator 1 Janssen Research & Development, LLC $75.00 05/02/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175381050
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,755.00 04/09/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,586.52 04/08/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 04/01/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,382.10 04/01/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,489.78 04/01/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,440.40 04/01/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,715.49 04/01/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,939.04 04/01/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,348.60 03/25/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178794
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 03/21/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192109580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,113.95 03/19/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $41,172.30 03/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,829.86 03/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,663.95 03/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $777.24 03/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.65 03/14/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,923.88 03/11/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,318.12 03/04/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156634
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $500.00 02/26/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067775
Principal investigator 1 Janssen Research & Development, LLC $11,636.00 02/19/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,045.80 02/18/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,720.92 02/11/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153046
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/05/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,517.38 02/05/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152510
Principal investigator 1 Janssen Research & Development, LLC $700.00 01/31/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175381057
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,134.40 01/29/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185548499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,337.56 01/29/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149972
Principal investigator 1 Eli Lilly and Company $1,039.97 01/27/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187887372
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $977.40 01/24/2025 Non-covered Recipient Entity
Olive Branch Family Medical Center
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066431
Principal investigator 1 Janssen Research & Development, LLC $6,924.00 01/22/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237594
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 01/21/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634468
Principal investigator 1 F. Hoffmann-La Roche AG $10,500.00 01/21/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634471
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 01/21/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211634504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,661.75 01/21/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149150
Principal investigator 1 AstraZeneca Pharmaceuticals LP $55,713.50 01/17/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185548497
Principal investigator 1 Janssen Research & Development, LLC $5,224.00 01/17/2025 Non-covered Recipient Entity
Olive Branch Fmly Medcl Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,959.20 01/17/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148219
Principal investigator 1 Eli Lilly and Company $84,627.00 01/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187886850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,932.46 01/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,479.60 01/07/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146026
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $39,283.70 01/01/2025 Non-covered Recipient Entity
OLIVE BRANCH FAMILY MEDICAL CENTER
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214124808